Nosocomial Pneumonia- Pipeline Insight, 2024

Nosocomial Pneumonia- Pipeline Insight, 2024

DelveInsight’s, “Nosocomial Pneumonia- Pipeline Insight, 2024” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Nosocomial Pneumonia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Nosocomial Pneumonia: Understanding

Nosocomial Pneumonia: Overview

Nosocomial pneumonia or hospital-acquired pneumonia (HAP) is defined as pneumonia that occurs 48 hours or more after hospital admission and not incubating at the admission time. HAP occurs at a rate of 5 to 10 per 1000 hospital admissions and is considered the most common cause of hospital-acquired infection in Europe and the United States. Over 90% of pneumonia episodes developing in ICUs occur in patients who are intubated and mechanically ventilated. Establishing the diagnosis of HAP remains controversial, and there is no superior method. In the guidelines for the management of HAP and VAP by Infectious Diseases Society of America/American Thoracic Society 2016, diagnosis is based upon a presence of new lung infiltrate and clinical evidence that the infiltrate is of an infectious cause (new onset of fever, purulent sputum, leukocytosis, and a decline in oxygenation). Clinical pulmonary infection score (CPIS), which includes clinical and radiological criteria, is suggested to increase the likelihood of the presence of pneumonia, but some investigators suggest that the CPIS while being sensitive, lacks specificity and leads to unnecessary antimicrobial treatment. Symptoms may include cough, expectoration, and a rise in body temperature, chest pain or dyspnea. Signs include fever, tachypnea, consolidations or crackles. For patients with HAP who have a risk factor for MRSA infection, specifically those with prior intravenous antibiotic use within 90 days, hospitalization in a unit where greater than 20% of S. aureus isolates are methicillin resistant, or the prevalence of MRSA is not known, or who are at high risk for mortality, prescribe an antibiotic active against MRSA like vancomycin or linezolid is recommended (weak recommendation, very low-quality evidence). Risk factors for mortality include the need for ventilator support due to HAP and septic shock. All patients with HAP or VAP should be reevaluated for clinical response and the microbiologic results after initial empiric antimicrobial therapy. Many studies have found that HAP is associated with an increased risk of death.

""Nosocomial Pneumonia- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nosocomial Pneumonia pipeline landscape is provided which includes the disease overview and Nosocomial Pneumonia treatment guidelines. The assessment part of the report embraces, in depth Nosocomial Pneumonia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nosocomial Pneumonia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Nosocomial Pneumonia R&D. The therapies under development are focused on novel approaches to treat/improve Nosocomial Pneumonia.

Nosocomial Pneumonia Emerging Drugs Chapters

This segment of the Nosocomial Pneumonia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nosocomial Pneumonia Emerging Drugs

• Tosatoxumab: Aridis Pharmaceuticals

Tosatoxumab (AR-301, Salvecin) is an intravenous, broadly active, human monoclonal antibody (IgG1λ) that targets the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin. The drug is in Phase III clinical developmental studies for the treatment of Nosocomial Pneumonia.

• Suvratoxumab: AstraZeneca

Suvratoxumab is a human immunoglobulin G1 kappa monoclonal antibody with an extended half-life, targeted pore-forming α toxin of Staphylococcus aureus. The drug is in Phase II clinical studies for the treatment of Nosocomial Pneumonia.

• Rifabutin: BioVersys

Rifabutin (BV100) has a novel mode of action addressing carbapenem resistant Acinetobacter baumannii (CRAB) lung and blood stream infections. Currently the drug is in Phase I of stage of development for the treatment of Nosocomial Pneumonia.

• CMTX 101 : Clarametyx Biosciences

Clarametyx’s pioneering therapy, CMTX-101, is a monoclonal antibody designed to rapidly collapse bacterial biofilms – protective shields that coat bacterial pathogens and help make them resistant to the effects of antibiotics and immune response. CMTX-101 targets a region of DNABII binding proteins that are essentially identical across all pathogenic bacteria. Bacterial DNABII proteins stabilize and maintain the integrity of bacterial biofilms. Precisely targeting this region on the DNABII proteins rapidly collapses biofilms, rendering the bacteria more vulnerable to the effects of antibiotics and the immune system. Currently, the drug is in Pre-Clinical stage of development for the treatment of nosocomial pneumonia.

Further product details are provided in the report……..

Nosocomial Pneumonia: Therapeutic Assessment

This segment of the report provides insights about the different Nosocomial Pneumonia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Nosocomial Pneumonia

There are approx. 13+ key companies which are developing the therapies for Nosocomial Pneumonia. The companies which have their Nosocomial Pneumonia drug candidates in the most advanced stage, i.e. phase III include, Aridis Pharmaceuticals.

• Phases

DelveInsight’s report covers around 13+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Nosocomial Pneumonia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nosocomial Pneumonia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nosocomial Pneumonia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nosocomial Pneumonia drugs.

Nosocomial Pneumonia Report Insights

• Nosocomial Pneumonia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Nosocomial Pneumonia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Nosocomial Pneumonia drugs?
• How many Nosocomial Pneumonia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nosocomial Pneumonia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nosocomial Pneumonia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Nosocomial Pneumonia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Aridis Pharmaceuticals
• AstraZeneca
• BioVersys
• Clarametyx Biosciences

Key Products

• Suvratoxumab
• Tosatoxumab
• Rifabutin
• CMTX 101

Show more